AstraZeneca Submits For New Dosage Strengths Of Atacand Plus - New Dosing Regimen Offers Patients Greater Chance To Reach Target Blood Pressure
Jul 4th 2008Drug InformationHypertension
AstraZeneca announced a European decentralized procedure (DCP) submission seeking approval for two new dose strengths of Atacand Plus, for those hypertensive patients not optimally controlled by monotherapy. The reference member state for the procedure is Sweden, and the submission incorporates data from three studies. 1,2,3 The new strengths of the fixed dose combination Atacand Plus, comprised of candesartan cilexetil and hydrochlorothiazide (HCT) in doses of 32/12.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
